Home » Unicancer research » Unicancer R&D » Unicancer R&D publications » Communications orales et posters

Unicancer R&D oral communications and posters

2018

UCGI 34 - PROSCORE: A prospective study assessing whether Immunoscore® Colon test impacts the choice of adjuvant ...

David Malka et al, ESMO

2018

PRODIGE 29 - UCGI 26 - NEOPAN: - A Randomised trial of chemotherapy with Folfirinox or gemcitabine in locally ...

Michel Ducreux et al, ESMO

2018

The UCGI 28 PANIRINOX trial - a randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and ...

T. Mazard et al, ESMO

2018

A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in ...

Jaafar Bennouna et al., ASCO

2018

FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver ...

E. Lopez-Crapez et al., ASCO

2018

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS ...

M. Ychou et al., ASCO

2018

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant ...

Conroy et al., ASCO

2018

Résultats d’une large étude de phase III multicentrique française – association chimio-hyperthermie ...

Quenet et al., ASCO

2018

PRODIGE 14-ACCORD 21 (METHEP-2) : essai sur le bénéfice d’une triple chimiothérapie d’induction par FOLFIRINOX ...

Ychou et al., ASCO

2018

PRODIGE 14-ACCORD 21 (METHEP2) : analyse de sous-groupe sur le bénéfice d’une triple chimiothérapie par FOLFIRINOX ...

Lopez-Crapez et al., ASCO